Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

PURPOSE: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism. PATIENTS AND METHODS: O...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Irvin, William J., Walko, Christine M., Weck, Karen E., Ibrahim, Joseph G., Chiu, Wing K., Dees, E. Claire, Moore, Susan G., Olajide, Oludamilola A., Graham, Mark L., Canale, Sean T., Raab, Rachel E., Corso, Steven W., Peppercorn, Jeffrey M., Anderson, Steven M., Friedman, Kenneth J., Ogburn, Evan T., Desta, Zeruesenay, Flockhart, David A., McLeod, Howard L., Evans, James P., Carey, Lisa A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2011
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3158597/
https://ncbi.nlm.nih.gov/pubmed/21768473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.4427
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares